Buprenorphine for the Neonatal Abstinence Syndrome
- PMID: 28877016
- PMCID: PMC6424493
- DOI: 10.1056/NEJMc1709121
Buprenorphine for the Neonatal Abstinence Syndrome
Conflict of interest statement
Since publication of their article, the authors report no further potential conflict of interest.
Comment on
-
Buprenorphine for the Neonatal Abstinence Syndrome.N Engl J Med. 2017 Sep 7;377(10):996. doi: 10.1056/NEJMc1709121. N Engl J Med. 2017. PMID: 28877015 No abstract available.
-
Buprenorphine for the Neonatal Abstinence Syndrome.N Engl J Med. 2017 Sep 7;377(10):996. doi: 10.1056/NEJMc1709121. N Engl J Med. 2017. PMID: 28880502 No abstract available.
-
Buprenorphine for the Neonatal Abstinence Syndrome.N Engl J Med. 2017 Sep 7;377(10):996-7. doi: 10.1056/NEJMc1709121. N Engl J Med. 2017. PMID: 28880503 No abstract available.
References
-
- Marek E, Adeniyi-Jones SC, Roke L, et al. Ethanol pharmacokinetics in neonates secondary to medication administration. Presented at the American Academy of Pediatrics Meeting, Washington, DC, October 24, 2015. abstract (http://jdc.jefferson.edu/petposters/1/).
-
- Committee on Drugs. Ethanol in liquid preparations intended for children. Pediatrics 1984; 73: 405–7. - PubMed
-
- Questions and answers on ethanol in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of medicinal products for human use’ (CPMP/463/00). London: European Medicines Agency, 2014. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical